Investor Presentaiton
3
Powering a New Decade of DNA Medicines
Precisely Designed Plasmids Delivered
Through Proprietary Smart Device
Safe and Robust Immune Responses
in More Than 2,000 Patients
DNA VACCINES
FIRST & ONLY COVID-19 Vaccine to Show
Long-Term Protection Against Live Virus in NHPs
13-Weeks Post-Vaccination (INO-4800)
FIRST Vaccine to Generate Immune Response
Against COVID-19 Variant D614G (INO-4800)
SADIDINE
INOVIO
In Vivo Immune Responses for
"Off-the-Shelf" Speed, Efficiency
Extensive Patent Portfolio
Protecting Technology Platform
DNA IMMUNOTHERAPIES
FIRST to Show Clearance of High-Risk
HPV 16/18 in Phase 2b Trial (VGX-3100)
FIRST DNA Medicine in Phase 3 Clinical Trials
(VGX-3100 for Precancerous Cervical Dysplasia)
FIRST Vaccine in Phase 2
for Middle East Respiratory Syndrome (INO-4700)
FIRST DMAb TM Plasmid in Phase 1
for Zika (INO-A002)
FIRST to Show Complete Response in Phase 1
w/2 PD-1s for Head and Neck Cancer (MEDI0457)
FIRST DNA Medicine to Show Potential for
Efficacy in GBM (INO-5401)
INOVIO
POWERING DNA MEDICINESView entire presentation